Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own one of the large cap biotechs, you are betting that…
Here are 5 ASX biotechs expecting clinical trial results in the next few months!
Dimerix (ASX:DXB)
Dimerix is in the middle of a Phase III trial or its DMX-200 drug…
